The shares of Corporate Office Properties Trust (NYSE:OFC) has been pegged with a rating of Underweight by KeyBanc Capital Markets in its latest research note that was published on April 23rd, 2019. The research company has also assigned a $23 price target. KeyBanc Capital Markets wasn’t the only research firm that published a report of Corporate Office Properties Trust, with other equities research analysts also giving their opinion on the stock. Robert W. Baird advised investors in its research note published on January 9th, 2019, to Outperform the OFC stock. The stock had earned Hold rating from Stifel when it published its report on January 4th, 2019. The stock was given Overweight rating by JP Morgan in its report released on December 19th, 2018. BofA/Merrill was of a view that OFC is Neutral in its latest report on November 30th, 2018. BofA/Merrill thinks that OFC is worth Buy rating. This was contained in the firm’s report on October 29th, 2018 in which the stock’s price target was also moved to $31.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 9 believe it has the potential for further growth, thus rating it as Hold while 3 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $28.42. The price of the stock the last time has raised by 43.85% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 61.18.
The shares of the company added by 0.84% during the trading session on Tuesday, reaching a low of $28.49 while ending the day at $28.82. During the trading session, a total of 1.41 million shares were traded which represents a -240723% decline from the average session volume which is 586.15K shares. OFC had ended its last session trading at 28.58. Corporate Office Properties Trust currently has a market cap of $3.22B, while its P/E ratio stands at 40.48, while its P/E earnings growth sits at 5.63, with a beta of 1.00. Corporate Office Properties Trust debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at . OFC 52-week low price stands at $20.03 while its 52-week high price is $31.01.
The company in its last quarterly report recorded $0.50 earnings per share which is below the $0.50 predicted by most analysts. The Corporate Office Properties Trust generated $131.99 million in revenue during the last quarter, which is slightly lower than the $132.39 million predicted by analysts. In the second quarter last year, the firm recorded $0.50 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by 0%. Corporate Office Properties Trust has the potential to record 0.71 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Mizuho published a research note on November 30th, 2018 where it informed investors and clients that Assertio Therapeutics, Inc. (NASDAQ:ASRT) is now rated as Neutral. Robert W. Baird also rated ASRT as Upgrade on January 9th, 2019, with its price target of $66 suggesting that ASRT could surge by 52.84% from its current share price. Even though the stock has been trading at $3.09/share, analysts expect it to surge higher by 2.27% to reach $6.70/share. It started the day trading at $3.23 and traded between $3.06 and $3.16 throughout the trading session.
A look at its technical shows that ASRT’s 50-day SMA is 4.16 while its 200-day SMA stands at 4.74. At the moment, only of Assertio Therapeutics, Inc. shares were sold short. The company’s average trading volume currently stands at 938.91K shares, which means that the short-interest ratio is just 8.86 days. Over the past seven days, the company moved, with its shift of -1.56%. Looking further, the stock has dropped -19.18% over the past 90 days while it lost -26.00% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. BlackRock Fund Advisors sold more ASRT shares, decreasing its portfolio by -0.04% during the last quarter. This move now sees BlackRock Fund Advisors selling -4,061 shares in the last quarter, thus it now holds 9,795,124 shares of ASRT, with a total valuation of $28,699,713. The Vanguard Group Inc meanwhile bought more ASRT shares in the recently filed quarter, changing its stake to $16,933,580 worth of shares. Renaissance Technologies LLC followed the path by increasing its ASRT portfolio by +10.98% in the quarter. This means that Renaissance Technologies LLC bought 512,836 shares in the last quarter and now controls 5,181,427 shares of the ASRT stock, with the valuation hitting $15,181,581.
Similarly, Connor Clark Lunn Investment M decreased its Assertio Therapeutics, Inc. shares by -1.79% during the recently filed quarter. After selling -57,059 shares in the last quarter, the firm now controls 3,134,905 shares of Assertio Therapeutics, Inc. which are valued at $9,185,272. In the same vein, SSgA Funds Management Inc increased its Assertio Therapeutics, Inc. shares by during the most recent reported quarter. The firm bought 218,684 shares during the quarter which increased its stakes to 2,155,848 shares and is now valued at $6,316,635. Following these latest developments, around 1.20% of Assertio Therapeutics, Inc. stocks are owned by institutional investors and hedge funds.